Pharmaceuticals

Marinus Pharma

Marinus Pharma released FY2024 Q3 earnings on November 12 (EST), actual revenue $8.541M (forecast $9.422M), actual EPS -0.4232 (forecast -0.417)

Marinus Pharma released FY2024 9 Months Earnings on November 12, 2024 (EST), with actual revenue of 24.28M USD and EPS of -1.7334

Marinus Pharmaceuticals Releases Key Clinical Data on Refractory Status Epilepticus RAISE Trial

Faruqi & Faruqi, LLP is investigating potential claims against Marinus Pharmaceuticals, Inc. for violations of federal securities laws

Marinus Pharmaceuticals, Inc. files securities fraud class action lawsuit

Reminder of Deadline in Class Action Lawsuit Against Marinus Pharmaceuticals, Inc.

Pomerantz LLP announces class action lawsuit against Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Securities Class Action Lawsuit

Marins Pharmaceuticals Securities Class Action Lawsuit

Marinus Pharmaceuticals faces securities class action lawsuit

Marinus Pharmaceuticals, Inc. faces class-action lawsuit

Shareholders File Class Action Lawsuit Against Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals announces positive results from Phase 3 trial of IV ganaxolone for the treatment of refractory status epilepticus (RSE)

Marinus Pharmaceuticals receives a consensus rating of 'hold' from seven research firms

RBC Capital Analyst Downgrades Marinus Pharma Rating to Sector Perform

Analysis of Analyst Ratings and Target Prices for Marinus Pharma

Marinus Pharmaceuticals Announces Continuation of Phase III RAISE Trial for IV Ganaxolone in Severe Epilepsy

RBC Capital reiterates Outperform rating on Marinus Pharma

HC Wainwright & Co. analyst reiterates Buy rating on Marinus Pharma

Luminar Tech

Novabay Pharmac

Mint Incorporation

Autozi Internet Tech Global

GD Culture

Impact BioMedical

Tradr 2X Long FLY Daily ETF

Leverage Shares 2X Long CRWV Daily ETF

T-REX 2X Long CRWV Daily Target ETF

Eli Lilly

ROCHE HOLDINGS AG

Roche

Astrazeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap